HRMY.NASDAQHarmony Biosciences Holdings, INC

Form 4: Harmony Biosciences CFO Sells Shares Post-Option Exercise

Sentiment:

Insider Transaction Report 9 December 2025 4:10 PM

📋All filings for Harmony Biosciences Holdings, INC

Harmony Biosciences' Chief Financial Officer, Sandip Kapadia, exercised stock options and subsequently sold 20,000 shares of common stock under a Rule 10b5-1 trading plan.

Summary

Sandip Kapadia, Chief Financial Officer of Harmony Biosciences Holdings, Inc. (HRMY), reported a change in beneficial ownership.
On December 5, 2025, Kapadia exercised stock options to acquire 20,000 shares of common stock at an exercise price of $29.03 per share.
Concurrently, on December 5, 2025, Kapadia sold all 20,000 of these shares of common stock at a weighted average price of $39.5448 per share.
The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan.
Following these transactions, Kapadia directly owns 0 shares of common stock.
Kapadia continues to beneficially own 185,000 derivative securities in the form of stock options.

Sentiment

Score: 5

Explanation: The transaction is a routine insider sale executed under a pre-arranged 10b5-1 trading plan, which typically reduces the perception of opportunistic selling and does not inherently signal a positive or negative outlook on the company's future performance.

Positives

The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction not based on immediate material non-public information.

Negatives

Insider selling, even if pre-planned, can sometimes be perceived negatively by investors, though the 10b5-1 plan mitigates this concern.

Future Outlook

Industry Context

Stakeholder Impact

Shareholders: May observe a routine insider sale, which is generally not considered a strong signal due to the 10b5-1 plan, but could lead to minor shifts in sentiment.

Key Dates

Date	Description
03/23/2023	50% of the underlying shares from the stock option vested.
04/23/2023	Remaining shares from the stock option began vesting in twenty-four equal monthly installments.
12/05/2025	Date of stock option exercise and subsequent sale of common stock.
12/09/2025	Date the Form 4 filing was signed.
03/29/2031	Expiration date of the stock option.

Recommendation

hold

The filing details a pre-planned insider sale by the CFO, which is a routine event and does not provide new fundamental information to alter an investment recommendation. The sale was executed under a Rule 10b5-1 trading plan, suggesting it was not based on new material non-public information.

Keywords

Harmony Biosciences, HRMY, Sandip Kapadia, CFO, Insider Trading, Stock Option Exercise, Share Sale, 10b5-1 Plan, SEC Form 4

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.